- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Cambridge Major Laboratories acquires ChemShop
Cambridge Major Laboratories has acquired ChemShop BV, a supplier of API development services, and plans to invest millions of dollars to expand the company's facilities.
Cambridge Major Laboratories (US) has acquired ChemShop BV (the Netherlands), a supplier of API development services. The newly combined company has over 140 employees at 3 sites in the US and Europe. ChemShop will adopt the name Cambridge Major Laboratories Europe.
All of ChemShop's management and personnel will continue to operate the business at the pre-existing Weert (Netherlands) facility, which includes R&D laboratories, GMP kilo lab suites, and a GMP pilot plant.
Cambridge Major plans to invest several million dollars to expand the European site to include more reactor capacity, laboratories, and expansion of the company's high potency API ("HPAPI") manufacturing capabilities. The planned expansion will commence immediately and be completed in the second half of 2008.
FDA Approves Subcutaneous Tecentriq Hybreza for All Adult Indications of IV Form of Tecentriq
September 13th 2024Subcutaneous Tecentriq Hybreza will provide patients and physicians increased flexibility for administration of the immunotherapy across approved indications for Tecentriq, including non–small cell lung cancer, small cell lung cancer, and hepatocellular carcinoma.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
